NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Developmenthttp://www.reportlinker.com/p087184/Stem-Cells-Worldwide-Markets-for-Transplantation-Cord-Blood-Banking-and-Drug-Development.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.
For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government's policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:
- Stem Cells in Drug Development
- Stem Cells in Cord Blood Banking
- Stem Cell Therapeutics
Stem cell therapeutics potentials are provided, broken down by disease:
- Cardiovascular disease
- Lung disease
- Tooth disease
- Arthritis
- Wrinkles/aging skin
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Bladder disease
- Infertility
- Orthopedics
- Alzheimer's disease
- Burns (severe)
- Lupus
- Parkinson's disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Intestinal disease
- Sickle cell disease
- Multiple myeloma
- NH Lymphoma
- Leukemia
The following trends are discussed in this report:
- Ethical Questions
- U.S. – State and Federal Initiatives
- Research Funding
- Cord Blood Initiatives
- International Initiatives
- Stem Cell Patents
- Other Healthcare Regulations
CHAPTER ONE: EXECUTIVE SUMMARY
Scope and Methodolgy
Introduction
Current Stem Cell Therapies
Developmental Stem Cell Therapies
Issues In Stem Cell Research
Stem Cell Forecasts
CHAPTER TWO: INTRODUCTION
The Promise of Stem Cells In Medical Treatment
Types of Stem Cells
Embryonic Stem Cells
Adult Stem Cells
Cord Blood Stem Cells
Stem Cell Harvesting
Embryonic Stem Cells
Therapeutic Cloning
Unfertilized Eggs
Adult Stem Cells
Leukapheresis
Peripheral Blood
Cord Blood Stem Cells
Transplantation Approaches
Autologous Transplantation
Allogenic Transplantation
Transplantation Procedures
Cancerous Stem Cells
Other Harmful Stem Cells
Stem Cells in Drug Development
Stem Cell Therapeutics
Stem Cells Targeting Drugs
Stem Cell Generated Organs
CHAPTER THREE: CURRENT STEM CELL THERAPIES
Cancer
Leukemia
Gene Therapy
Multiple Myeloma
Non-Hodgkin's Lymphoma
Non Cancerous Diseases
Aplastic anemia
Immunodeficiency
Lupus
Sickle Cell Disease
Other Conditions
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
Alzheimer's Disease
Arthritis
Bladder Disease
Burns
Cancer
Cardiovascular Conditions
Critical Limb Ischemia
Diabestes
Esophagal Disease
Incontinence
Infertility
Intestinal Disease
Liver Failure
Lung Disease
Multiple Sclerosis
Orthopedics
Osteoporosis
Parkinson's Disease
Sickle Cell Disease
Tooth Disease
Wrinkles/Aging Skin
CHAPTER FIVE: STEM CELL FORECASTS
Best Case
Stem Cell Therapeutics
Umbilical Cord Blood Banking
Fees Related to Drug Development
Most Likely Case
Stem Cell Therapeutics
Umbilical Cord Blood Banking
Fees Related to Drug Development
Worst Case
Stem Cell Therapeutics
Umbilical Cord Blood Banking
Fees Related to Drug Development
CHAPTER SIX: ISSUES IN STEM CELL RESEARCH
Ethical Questions
U.S. - State and Federal Initiatives
Research Funding
Federal Funding
State Funding
Cord Blood Initiatives
International Initiatives
Stem Cell Patents
Other Healthcare Regulations
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 - 2020
Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 - 2020
Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 - 2020
Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 - 2020
Figure 1-1 Total Market for Stem Cells - Most Likely Case in $ Millions, 2010 - 2020
CHAPTER TWO: INTRODUCTION
Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010
CHAPTER THREE: CURRENT STEM CELL THERAPIES
Table 3-1 Types of Leukemia, 2011
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011
Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020
Table 4-4 Features and Types of Urinary Incontinence, 2011
Table 4-5 Types and Causes of Male Infertility, 2011
Table 4-6 Common Diseases of the Lungs, 2011
CHAPTER FIVE: STEM CELL FORECASTS
Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011
Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 - 2020
Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020
Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 - 2020
Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020
Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020
Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020
Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020
CHAPTER SIX: ISSUES IN STEM CELL RESEARCH
Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in $ Million
Table 6-2 U.S. State Embryonic & Fetal Research Laws
Table 6-3 Positions on Human ES Cell Research by Country, 2011
Table 6-4 EU Laws on hESC Research by Country
To order this report:Blood Supply, Tissue Banking and Transplantation Industry: Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug DevelopmentMore Market Research ReportCheck our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker